Considerations regarding antiretroviral chemoprophylaxis in MSM

Current Opinion in HIV and AIDS

Volumn 7, Issue 6, 2012, Pages 549-556

  Poynten, I Mary ^a   Zablotska, Iryna ^a   Grulich, Andrew E ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

antiretroviral; HIV; MSM; preexposure prophylaxis; prevention

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIMALARIAL AGENT; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; MARAVIROC; ORAL CONTRACEPTIVE AGENT; PLACEBO; RILPIVIRINE; TENOFOVIR DISOPROXIL;

ANTIVIRAL THERAPY; CHEMOPROPHYLAXIS; DISEASE MODEL; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG INTERMITTENT THERAPY; DRUG MONITORING; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; HIGH RISK BEHAVIOR; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; MALARIA; MALE HOMOSEXUAL; NONHUMAN; PATIENT COMPLIANCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM; REVIEW; UNSPECIFIED SIDE EFFECT; VIRUS TRANSMISSION;

ADENINE; ADMINISTRATION, ORAL; ANIMALS; ANTI-HIV AGENTS; CHEMOPREVENTION; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; DRUG TOXICITY; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MEDICATION ADHERENCE; ORGANOPHOSPHONATES; PLASMA; TREATMENT OUTCOME;

EID: 84868451982     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283582c71     Document Type: Review

References (54)

1. Grulich A, Kaldor J. Trends in HIV incidence in homosexual men in developed countries. Sex Health 2008; 5:113-118.
2. Guy R, McDonald A, Bartlett M, et al. Characteristics of HIV diagnoses in Australia, 1993-2006. Sex Health 2008; 5:91-96.
3. Baggaley R, White R, Boily M. HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol 2010; 39:1048-1063.
4. Zablotska I, Prestage G, Grulich A, Imrie J. Differing trends in sexual risk behaviours in three Australian states: New South Wales, Victoria, Queensland, 1998-2006. Sex Health 2008; 5:125-130.
5. Dosekun O, Fox J. An overview of the relative risks of different sexual behaviours on HIV transmission. Curr Opin HIV AIDS 2010; 5:291-297.
6. Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA 2008; 300:520-529.
7. Fauci A. Pathogenesis of HIV disease: opportunities for new prevention interventions. Clin Infect Dis 2007; 45 (Supp 4):S206-S212.
8. Ross D. Behavioural interventions to reduce HIV risk: what works? AIDS 2010; Suppl4:S4-S14.
9. Berg R. The effectiveness of behavioural and psychosocial HIV/STI prevention interventions for MSM in Europe: a systematic review. Euro Surveill 2009; 4:ii19430.
10. Grant R, Lama J, Anderson P, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587- 2599.
11. Gallant J, DeJesus E, Arribas J, et al. emtricitabine and efavirenz vs zidovudine, lamivudine and efavirenz for HIV. N Engl J of Med 2006; 354:251-260.
12. Hawkins T, Veikley W, St Claire R, et al. Intracellular pharmacokinetics of tenofovir disphosphate, carbovir triphosphate and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr 2005; 39:406-411.
13. Vourvahis M, Tappouni H, Patterson K, et al. The pharmacokinetics and viral activity of tenofovir in the male genital tract. J Acquir Immune Defic Syndr 2008; 47:329-333.
14. García-Lerma J, Otten R, Qari S, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 2008; 5:e28.
15. García-Lerma J, Cong M, Mitchell J, et al. Intermittent prophylaxis with oral Truvada protects macaques from rectal SHIV infection. Sci Transl Med 2010; 2:14ra4 p.
16. Patterson KB, Prince HA, Kraft E, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Science Translational Medicine. 2011; 3:112re4.
17. Jackson A, Else L, Tija J, et al. Rilpavirine-LA formulation: pharmacokinetics in plasma, genital tract in HIV-females and rectum in males. In: Proceedings of the 19th Conference on Retroviruses and Opportunistic Infections; 5-8March; Seattle, Washington; 2012.
18. Otten R, Smith D, Adams D, et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol 2000; 74:9771- 9775.
19. Tsai C, Follis K, Sabo A, et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). Science 1995; 270:1197-1199.
20. Tsai C, Emau P, Follis K, et al. Effectiveness of postinoculation (R)-9-(2- Phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus infection depends critically on timing of initiation and duration of treatment. J Virol 1998; 72:4265-4273.
21. Guay L, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354:795-802.
22. Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet 2002; 359:1178-1186.
23. Roland M. Postexposure prophylaxis after sexual exposure to HIV. Curr Opin Infect Dis 2007; 20:39-46.
24. Taha T, Kumwenda N, Gibbons A, et al. Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV- NVAZ randomised clinical trial. Lancet 2003; 362:1171-1177.
25. Cardo D, Culver D, Ciesielski C, et al. A case-control study of HIV seroconversion in healthcare workers after percutaneous exposure New England. J Med 1997; 337:1485-1490.
26. Kahn J, Martin J, Roland M, et al. feasibility of postexposure prophylaxis (pep) against human immunodeficiency virus infection after sexual or injection drug use exposure: The San Francisco PEP Study. J Infect Dis 2001; 183:707- 714.
27. Bernasconi E, Jost J, Ledergerber B, et al. Antiretroviral prophylaxis for community exposure to the human immunodeficiency virus in Switzerland, 1997-2000. Swiss Med Wkly 2001; 131:433-437.
28. Martin J, Roland M, Neilands T, et al. Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. AIDS 2004; 18:787-792.
29. Tissot F, Erard V, Dang T, Cavassini M. Nonoccupational HIV postexposure prophylaxis: a 10-year retrospective analysis. HIV Med 2010; 11:584- 592.
30. Poynten I, Smith D, Cooper D, et al. The public health impact of widespread availability of nonoccupational postexposure prophylaxis against HIV. HIV Med 2007; 8:374-381.
31. Roland M. Enhancing the potential benefits of HIV postexposure prophylaxis. AIDS 2006; 20:1889-1890.
32. Schechter M, do Lago R, Mendelsohn A, et al. LH H. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr 2004; 35:519-525.
33. Poynten I, Jin F, Mao L, et al. Nonoccupational postexposure prophylaxis, subsequent risk behaviour and HIV incidence in a cohort of Australian homosexual men. AIDS 2009; 23:1119-1126.
34. Anderson P, Liu A, Buchbinder S, et al. Intracellular tenofovir-DP concentrations associated with PrEP efficacy in MSM from iPrEx. In: Proceedings of the 19th Conference on Retroviruses and Opportunistic Infections; 5-8 March; Seattle, Washington; USA 2012.
35. Myers G, Mayer K. Oral preexposure anti-HIV prophylaxis for high-risk US populations: current considerations in light of new findings. AIDS Patient Care STDS 2011; 25:63-71.
36. Grohskopf L, Gvetadze R, Pathak S, et al. Preliminary analysis of biomedical data from the phase II clinical safety trial of tenofovir disoproxil fumarate (TDF) for HIV-1 preexposure prophylaxis (PrEP) among US men who have sex with men (MSM). In: Proceedings of the XVIII International AIDS Conference; 18- 23 July 2010; Vienna, Austria.
37. Liu A, Vittinghoff E, Sellmeyer D, et al. Bone mineral density in HIV-negative men participating in a tenofovir preexposure prophylaxis randomized clinical trial in San Francisco. PLoS ONE 2011; 6:e23688. doi:10.1371/journal. pone.0023688 p.
38. French National Agency for Research on AIDS and Viral Hepatitis. IPERGAY study press release: Launch of first pre-HIV exposure prevention trial for gay men in Europe. 6 January 2012; Paris, France.
39. HIV Prevention Trials Network. HPTN studies. http://www.hptn.org/ research- studies.asp2012. http://www.hptn.org/research-studies.asp. [Accessed 14 June 2012]
40. AVAC global advocacy for HIV prevention. Ongoing and planned preexposure prophylaxis (PrEP) trials. http://www.avac.org/ht/d/sp/i/354/pid/354. [Accessed 14 June 2012]
41. Mayer K, Krakower D. Antiretroviral medication and HIV prevention: news steps forward and new questions. Ann Int Med 2012; 156:312- 314.
42. Centres for Disease Control and Prevention. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep 2011; 60:65-68.
43. Report of a WHO technical consultation. The strategic use of antiretrovirals for treatment and prevention of HIV infection. Geneva, Switzerland: WHO; November 2011.
44. McCormack S, Fidler S, Fisher M. The British HIV Association/British Association for sexual health and HIV position statement on preexposure prophylaxis in the UK. Int J STD AIDS 2012; 23:1-4.
45. van der Straten A, van Damme L, Haberer J, Bangsberg D. How well does PREP work? Unraveling the divergent results of PrEP trials for HIV prevention. AIDS 2012; 26:F13-F19.
46. Golub S, Operario D, Gorbach P. Preexposure prophylaxis state of the science: empirical analogies for research and implementation. Curr HIV/AIDS Rep 2010; 7:201-209.
47. Holt M, Murphy D, Callander D, et al. Willingness to use HIV preexposure prophylaxis and the likelihood of decreased condom use are both associated with unprotected anal intercourse and the perceived likelihood of becoming HIV positive among Australian gay and bisexual men. Sex Transm Infect 2012; 88:258-263.
48. Krakower D, Mimiaga M, Rosenberger J, et al. Limited awareness and low immediate uptake of preexposure prophylaxis among men who have sex with men using an internet social networking site. PLoS ONE 2012; 7:e33119.
49. Aghaizu A, Mercey D, Copas A, Johnson A, Hart G, Nardone A, editors. Who would use PrEP? Predictors of use among MSM in London [abstract 023]. In: Abstracts of the 18th Annual Conference of the British HIV Association (BHIVA); 18-20 April 2012; Birmingham, UK.
50. Golub S, Kowalczyk W, Weinberger C, Parsons J. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr 2010; 54:548-555.
51. Brooks R, Landovitz R, Kaplan R, et al. Sexual risk behaviors and acceptability of HIV preexposure prophylaxis among HIV-negative gay and bisexual men in serodiscordant relationships: a mixed methods study. AIDS Patient Care STDS 2012; 26:87-94.
52. Krakower D, Mayer K. Promising prevention approaches: tenofovir gel and prophylactic use of antiretroviral medications. Curr HIV/AIDS Rep 2011; 8:241- 248.
53. Flash C, Krakower D, Mayer K. The promise of antiretrovirals for HIV prevention. Curr Infect Dis Rep 2012; 14:185-193.
54. Eaton L, Kalichman S. Risk compensation in HIV prevention: implications for Vaccines, microbicides, and other biomedical HIV prevention technologies. Curr HIV/AIDS Rep 2007; 4:165-172.